Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is ending 2025 with something investors in AI-driven biotech rarely get in the same month: fresh clinical momentum, a high-profile Wall Street upgrade, and renewed attention from Cathie Wood’s ARK funds—all playing out during a shortened Christmas Eve trading session. As of December 24, 2025, RXRX stock is trading around $4.37, up modestly on the day, with a market capitalization near $2.12 billion. That price level may look quiet at a glance—until you zoom out to the drivers behind the tape: REC-4881’s Phase 1b/2 TUPELO readout in familial adenomatous polyposis (FAP), J.P. Morgan’s upgrade, ARK’s